ProCE Banner Activity

Overview of SDOH in NVAF and CV-Related Outcomes

Podcast Episodes

In this podcast, expert faculty David S. Kountz, MD, provides an overview of the impact of social determinants of health (SDOH) on nonvalvular atrial fibrillation (NVAF) and cardiovascular-related outcomes. Listen as Dr Kountz explains the atrial fibrillation paradox and how SDOH affect clinical outcomes in those with NVAF.

In Collaboration With the Academy of Physician Associates in Cardiology


Released: May 26, 2022

Expiration: May 25, 2023



Keith C. Ferdinand

Keith C. Ferdinand, MD, FACC, FAHA

Professor of Medicine
Tulane Heart and Vascular Institute
Tulane University School of Medicine
New Orleans, Louisiana

David S. Kountz

David S. Kountz, MD, MBA, MACP

Department of Medicine
Hackensack Meridian School of Medicine
Nutley, New Jersey

Laura Ross

Laura Ross, PA-C, MPAS, CLS, DipACLM, AACC

Director, Heart Disease Prevention and Lipid Clinic
Park Nicollet Heart and Vascular Center
St Louis Park, Minnesota


This activity is supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.

Provided by

ProCE Banner
ProCE Banner


This activity is supported by an educational grant from Bristol Myers Squibb and Pfizer Alliance.

Bristol Myers Squibb

Pfizer Alliance



ProCE Banner

Target Audience

This program is intended for cardiologists, primary care physicians, NP, PAs, and other healthcare professionals who care for patients with NVAF.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify SDOH that affect outcomes in cardiovascular and NVAF management


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Keith C. Ferdinand, MD, FACC, FAHA: consultant: Amgen, Boehringer Ingelheim, Medtronic, Novartis, Sanofi.

David S. Kountz, MD has no relevant financial relationships to disclose.

Laura Ross, PA-C, CLS has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.




The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.